Skip to content

Author

Alireza Dehghanmanshadi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.

BACKGROUND Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. OBJECTIVE To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort of consecu...

D. D. Shapiro, D. Roadman, V. Master et al. · 1 citation
Sep 2026

Development and internal validation of machine-learning models to predict adverse pathological features in upper tract urothelial carcinoma.

ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC and external validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.

Philipp Korn, Maximilian Pallauf, S. Lokeshwar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.